Biocept, Inc. (BIOCQ) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 3.98: the stock has moved about 298% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBiocept, Inc. (BIOCQ) trades at $0.0001. Biocept, Inc. is a molecular oncology diagnostics company that develops and commercializes clinical diagnostic laboratory assays. The company filed for Chapter 7 bankruptcy in October 2023 and is currently undergoing liquidation. Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for BIOCQ: BIOCQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BIOCQ against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
BIOCQ: 2/2 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Biocept, Inc. (BIOCQ) Healthcare & Pipeline Overview
Biocept, Inc. focuses on developing and commercializing molecular oncology diagnostics, including assays for identifying rare tumor cells and cell-free tumor DNA. The company's assays target various cancers, providing information for targeted therapy. Biocept filed for Chapter 7 bankruptcy in 2023 and is undergoing liquidation, impacting its market position.
What Is the Investment Thesis for BIOCQ?
Biocept, Inc. filed for Chapter 7 bankruptcy on October 13, 2023, and is currently undergoing liquidation. The company's negative profit margin of -124.1% and gross margin of -10.0% reflect significant financial challenges. The company's beta of 3.98 indicates high volatility. Investors should note the company's bankruptcy status and the implications for potential recovery or asset distribution. Given the liquidation process, traditional investment metrics may not be applicable. The company's future prospects are uncertain, contingent on the bankruptcy proceedings and any potential asset sales or restructuring.
Based on FMP financials and quantitative analysis
BIOCQ Key Highlights
Market Cap: $0.00B, reflecting the company's distressed financial state and ongoing liquidation.
- P/E Ratio: -0.01, indicating negative earnings and the company's lack of profitability.
- Profit Margin: -124.1%, highlighting significant losses and financial instability.
- Gross Margin: -10.0%, demonstrating that the company's cost of goods sold exceeded its revenue.
- Beta: 3.98, indicating high volatility compared to the market, likely exacerbated by the bankruptcy proceedings.
Who Are BIOCQ's Competitors?
BIOCQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| TMO Thermo Fisher Scientific Inc. | $609.82 | +1.10% | $227B | 645-pillar |
| DHR Danaher Corporation | $200.06 | -0.23% | $141B | 655-pillar |
| WUXAY WuXi AppTec Co., Ltd. | $24.50 | -0.39% | $71.0B | 449-signal |
| NTRA Natera, Inc. | $326.14 | -1.26% | $46.7B | 395-pillar |
| LZAGY Lonza Group AG | $65.61 | -1.20% | $46.7B | 449-signal |
| IQV IQVIA Holdings Inc. | $261.88 | +1.78% | $43.1B | 725-pillar |
| A Agilent Technologies, Inc. | $146.25 | +2.19% | $41.3B | 795-pillar |
| IDXX IDEXX Laboratories, Inc. | $506.53 | -1.67% | $40.0B | 905-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are BIOCQ's Key Strengths?
Proprietary clinical diagnostic laboratory assays
- Focus on molecular oncology diagnostics
- Testing services for various solid tumor indications
What Are BIOCQ's Weaknesses?
Chapter 7 bankruptcy filing
- Negative profit and gross margins
- Limited financial resources
What Could Drive BIOCQ Stock Higher?
Bankruptcy proceedings may lead to asset sales or licensing agreements.
- Potential for restructuring of debt and operations (unlikely).
What Are the Key Risks for BIOCQ?
Liquidation process may result in complete loss of investment.
- Competition from larger diagnostic companies.
- Technological obsolescence.
- Limited financial resources hinder future development.
What Are the Growth Opportunities for BIOCQ?
- Expansion of Liquid Biopsy Applications: Liquid biopsies are gaining traction in cancer diagnostics due to their non-invasive nature and ability to provide real-time monitoring of disease progression. Biocept could have explored expanding its liquid biopsy assays to cover a broader range of cancer types and stages, potentially tapping into a market projected to reach $7.1 billion by 2028. However, the bankruptcy filing prevents further development.
- Strategic Partnerships with Pharmaceutical Companies: Collaborating with pharmaceutical companies to develop companion diagnostics for targeted therapies could have provided a significant revenue stream. By offering assays that identify patients most likely to respond to specific drugs, Biocept could have positioned itself as a valuable partner in drug development. The global companion diagnostics market is expected to reach $8.7 billion by 2027.
- Geographic Expansion into International Markets: Expanding its services to international markets, particularly in Europe and Asia, could have diversified Biocept's revenue base and reduced its reliance on the US market. The increasing prevalence of cancer globally and the growing adoption of personalized medicine are driving demand for molecular diagnostics in these regions. However, the bankruptcy filing halts any international expansion plans.
- Development of New Diagnostic Assays: Investing in the development of new diagnostic assays for emerging biomarkers and cancer subtypes could have enhanced Biocept's competitive advantage. By staying at the forefront of scientific advancements, the company could have attracted new customers and expanded its market share. The market for new diagnostic assays is constantly evolving, driven by ongoing research and technological breakthroughs.
- Integration of Artificial Intelligence and Machine Learning: Incorporating AI and machine learning technologies into its diagnostic platforms could have improved the accuracy and efficiency of Biocept's assays. AI can be used to analyze complex genomic data and identify patterns that may be missed by human analysis, leading to more precise diagnoses and treatment decisions. The AI in healthcare market is projected to reach $45 billion by 2026.
What Opportunities Does BIOCQ Have?
- Potential for asset sales or licensing agreements
- Restructuring of debt and operations (unlikely)
- Future advancements in molecular diagnostics
What Are BIOCQ's Competitive Advantages?
- Proprietary clinical diagnostic laboratory assays.
- Focus on identifying rare tumor cells and cell-free tumor DNA.
- Testing services for a range of solid tumor indications.
What Does BIOCQ Do?
Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California. The company specialized in developing and commercializing proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid (CSF). These assays provided healthcare providers with information to identify oncogenic alterations, enabling targeted therapy for cancer patients at diagnosis, progression, and during monitoring to identify resistance mechanisms. Biocept offered assays for solid tumor indications, including breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. The company also provided cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to various medical professionals, including oncologists, neuro-oncologists, and pathologists. Biocept also offered clinical trial and research services to pharmaceutical and biopharmaceutical companies. The company had collaborations with CLEARED4 to develop a system for tracking COVID-19 testing and with Protean BioDiagnostics, Inc. to research EGFR status in NSCLC patients. However, on October 13, 2023, Biocept, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
What Products and Services Does BIOCQ Offer?
- Develops clinical diagnostic laboratory assays.
- Commercializes assays for identifying rare tumor cells.
- Identifies cell-free tumor DNA from blood and CSF.
- Offers assays for solid tumor indications like breast and lung cancer.
- Provides cerebrospinal fluid tumor cell testing services.
- Offers clinical trial and research services to pharmaceutical companies.
How Does BIOCQ Make Money?
- Develops and commercializes proprietary diagnostic assays.
- Generates revenue through sales of diagnostic testing services.
- Partners with pharmaceutical companies for clinical trials and research services.
What Industry Does BIOCQ Operate In?
Biocept operated in the molecular diagnostics market, which is characterized by rapid innovation and increasing demand for personalized medicine. The industry is driven by advancements in genomics and proteomics, leading to the development of more precise and effective diagnostic tools. Key competitors include BSPM, CRFTF, CWWBF, HTGMQ, and MDVLQ. However, Biocept's bankruptcy and liquidation significantly impact its competitive positioning within this landscape. The industry continues to grow, but Biocept's ability to participate is severely limited.
Who Are BIOCQ's Key Customers?
- Medical oncologists
- Neuro-oncologists
- Pathologists
- Pharmaceutical companies
- Biopharmaceutical companies
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 44 |
| 2026-08-26 | 44 |
| 2026-08-29 | 44 |
| 2026-09-01 | 44 |
| 2026-09-04 | 44 |
| 2026-09-07 | 44 |
| 2026-09-10 | 44 |
What changed?
The score has stayed at 44.
Over the same 18 days the stock moved +0.0%.
Company Profile
Biocept, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Soon Kap Hahn. BIOCQ has traded publicly since 2014.
Forward Outlook
Wall Street analysts project Biocept, Inc. revenue of about $44.9M for fiscal 2026, with EPS near $-0.10.
BIOCQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary clinical diagnostic laboratory assays
- Focus on molecular oncology diagnostics
- Testing services for various solid tumor indications
- Ongoing: Bankruptcy proceedings may lead to asset sales or licensing agreements.
Bear Case
- Chapter 7 bankruptcy filing
- Negative profit and gross margins
- Limited financial resources
- Ongoing: Liquidation process may result in complete loss of investment.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
BIOCQ Latest News
No recent news available for BIOCQ.
BIOCQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BIOCQ.
Price Targets
Wall Street price target analysis for BIOCQ.
BIOCQ MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BIOCQ; grades run from A+ (80-100) to F (below 30).
Leadership: Soon Kap Hahn
Chief Executive Officer
Soon Kap Hahn served as the Chief Executive Officer of Biocept, Inc. His background includes experience in managing teams and overseeing the operations of a molecular oncology diagnostics company. He was responsible for leading the company's strategic direction and overseeing the development and commercialization of its diagnostic assays. His leadership involved navigating the complexities of the healthcare industry and the challenges of a competitive market.
Track Record: Under Soon Kap Hahn's leadership, Biocept focused on developing and commercializing clinical diagnostic laboratory assays. However, the company ultimately filed for Chapter 7 bankruptcy in October 2023, indicating significant financial and operational challenges during his tenure. The company's liquidation reflects the difficulties in achieving sustainable profitability and market success.
BIOCQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Biocept, Inc. did not meet the requirements for the higher tiers (OTCQX and OTCQB). Companies in this tier may be distressed, undergoing bankruptcy, or have chosen not to comply with the disclosure requirements of the higher tiers. Trading on the OTC Other market carries significant risks due to the lack of regulatory oversight and limited financial disclosure compared to NYSE or NASDAQ-listed companies. Investors should exercise extreme caution when considering investments in this tier.
- OTC Tier: OTC Other
- Limited financial disclosure
- Low liquidity and wide bid-ask spreads
- Bankruptcy and liquidation proceedings
- Potential for delisting and loss of investment
- Lack of regulatory oversight
- Verify the company's bankruptcy status and court filings.
- Assess the potential for asset recovery or distribution.
- Review any available financial statements or disclosures.
- Understand the risks associated with OTC Other trading.
- Evaluate the company's management and governance structure.
- Consult with a financial advisor before investing.
- Consider the potential for complete loss of investment.
- Prior history as a publicly traded company
- Established operations in the molecular diagnostics industry
- Previous collaborations with pharmaceutical companies
BIOCQ Healthcare Stock FAQ
Is BIOCQ a good stock?
Stock Expert AI does not rate BIOCQ buy, sell or hold. Biocept, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the main risks for BIOCQ?
The primary risk for BIOCQ is the ongoing liquidation process under Chapter 7 bankruptcy. This process may result in a complete loss of investment for shareholders. Investors should carefully consider these risks before investing in BIOCQ.
What are the key factors to evaluate for BIOCQ?
Evaluate BIOCQ on fundamentals, analyst consensus, and risk factors. Biocept, Inc. filed for Chapter 7 bankruptcy on October 13, 2023, and is currently undergoing liquidation. Not financial advice.
How frequently does BIOCQ data refresh on this page?
BIOCQ's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BIOCQ's recent stock price performance?
Biocept, Inc. (BIOCQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary clinical diagnostic laboratory assays. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BIOCQ overvalued or undervalued right now?
Biocept, Inc. (BIOCQ) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of BIOCQ?
Yes, most major brokerages offer fractional shares of Biocept, Inc. (BIOCQ) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track BIOCQ's earnings and financial reports?
Biocept, Inc. (BIOCQ) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for BIOCQ earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change due to the bankruptcy proceedings.
- The company's financial condition is highly unstable due to the bankruptcy filing.